Mitchell Mcleod Pugh & Williams Inc. Buys 176 Shares of Amgen Inc. (NASDAQ:AMGN)

Mitchell Mcleod Pugh & Williams Inc. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 7.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,424 shares of the medical research company’s stock after purchasing an additional 176 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Amgen were worth $698,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of AMGN. BIP Wealth LLC increased its holdings in shares of Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock worth $360,000 after purchasing an additional 32 shares during the last quarter. Southland Equity Partners LLC raised its holdings in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after acquiring an additional 34 shares in the last quarter. Acropolis Investment Management LLC boosted its position in shares of Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after acquiring an additional 34 shares during the last quarter. Opal Wealth Advisors LLC grew its holdings in shares of Amgen by 1.9% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 34 shares in the last quarter. Finally, Marino Stram & Associates LLC increased its position in Amgen by 0.7% in the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after purchasing an additional 34 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Truist Financial reissued a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating for the company. Finally, UBS Group reduced their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $297.40.

Amgen Trading Up 2.4 %

NASDAQ AMGN opened at $276.38 on Tuesday. The company’s 50-day simple moving average is $274.96 and its two-hundred day simple moving average is $281.45. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a market capitalization of $148.24 billion, a price-to-earnings ratio of 22.13, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the firm posted $4.09 earnings per share. Amgen’s revenue for the quarter was up 19.8% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.26%. Amgen’s dividend payout ratio is presently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.